While multiple clinical trials are currently being conducted to reduce or overcome immune suppressive mechanisms in the tumor microenvironment, the molecular factors involved in CD8+ T-cell exclusion and ineffective tumor-associated antigen presentation in SCCHN are still not well understood. This evidence concerns the gene CD8A and head and neck squamous cell carcinoma.